Cargando…

Complement contributes to antibody-mediated protection against repeated SHIV challenge

The first clinical efficacy trials of a broadly neutralizing antibody (bNAb) resulted in less benefit than expected and suggested that improvements are needed to prevent HIV infection. While considerable effort has focused on optimizing neutralization breadth and potency, it remains unclear whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldberg, Benjamin S., Spencer, David A., Pandey, Shilpi, Ordonez, Tracy, Barnette, Philip, Yu, Yun, Gao, Lina, Dufloo, Jérémy, Bruel, Timothée, Schwartz, Olivier, Ackerman, Margaret E., Hessell, Ann J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193994/ https://www.ncbi.nlm.nih.gov/pubmed/37155897 http://dx.doi.org/10.1073/pnas.2221247120

Ejemplares similares

Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
por: Spencer, David A., et al.
Publicado: (2022)

Sex and species associated differences in Complement-mediated immunity in Humans and Rhesus macaques
por: Kelkar, Natasha S., et al.
Publicado: (2023)

Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity
por: Goldberg, Benjamin S., et al.
Publicado: (2021)

HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
por: Dufloo, Jérémy, et al.
Publicado: (2018)

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques
por: Hessell, Ann J., et al.
Publicado: (2016)

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines
por: Weiss, Svenja, et al.
Publicado: (2022)

Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge
por: Malherbe, Delphine C., et al.
Publicado: (2021)

Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
por: Rosenberg, Yvonne J., et al.
Publicado: (2023)

Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
por: Dufloo, Jérémy, et al.
Publicado: (2022)

Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
por: Shapiro, Mariya B., et al.
Publicado: (2020)

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
por: Vidal, Samuel J., et al.
Publicado: (2021)

CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge
por: Ariën, Kevin K., et al.
Publicado: (2016)

Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo
por: Crakes, Katti R, et al.
Publicado: (2020)

Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques
por: Lu, Pinyi, et al.
Publicado: (2021)

Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity
por: Prigent, Julie, et al.
Publicado: (2018)

Syncytia formation by SARS‐CoV‐2‐infected cells
por: Buchrieser, Julian, et al.
Publicado: (2020)

Syncytia formation by SARS‐CoV‐2‐infected cells
por: Buchrieser, Julian, et al.
Publicado: (2021)

T Cell Chemo-Vaccination Effects after Repeated Mucosal SHIV Exposures and Oral Pre-Exposure Prophylaxis
por: Kersh, Ellen N., et al.
Publicado: (2011)

OA021-02. Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV
por: Tangy, F, et al.
Publicado: (2009)

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques
por: Jaworski, Juan Pablo, et al.
Publicado: (2017)

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers
por: Hessell, Ann J., et al.
Publicado: (2009)

Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV
por: Garber, David A., et al.
Publicado: (2018)

Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
por: Hioe, Catarina E., et al.
Publicado: (2023)

Shiv Nadar School students visit CERN
por: Poulaillon, Jimmy, et al.
Publicado: (2023)

Oral Vaccination Approaches for Anti-SHIV Immunity
por: Velarde de la Cruz, Erandi, et al.
Publicado: (2021)

CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques
por: Sarkar, Sanghita, et al.
Publicado: (2021)

Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
por: Hioe, Catarina E., et al.
Publicado: (2023)

Antimicrobial prophylaxis does not improve post-surgical outcomes in SIV/SHIV-uninfected or SIV/SHIV-infected macaques (Macaca mulatta and Macaca fascicularis) based on a retrospective analysis
por: Moats, Cassandra, et al.
Publicado: (2022)

Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4(+) T Cells
por: Obregon-Perko, Veronica, et al.
Publicado: (2020)

In memory of a Legend: Dr. Shiv Shankar Gupta
por: Chandra, Dinesh
Publicado: (2013)

SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies
por: Martin, Malcolm A
Publicado: (2013)

Prevention of SHIV transmission by topical IFN-β treatment
por: Veazey, Ronald S., et al.
Publicado: (2016)

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
por: Sholukh, AM, et al.
Publicado: (2012)

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
por: Sholukh, Anton M, et al.
Publicado: (2014)

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
por: Dufloo, Jérémy, et al.
Publicado: (2021)

Vaccination-Induced Noncytolytic Effects in the Acute Phase of SHIV Infection
por: Petravic, Janka, et al.
Publicado: (2010)

Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission
por: Chang, Xiao L., et al.
Publicado: (2021)

Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV
por: Marshall, Vickie A., et al.
Publicado: (2018)

A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2022)

Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge
por: Om, Kier, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vaumeo15i651cna3i2e2mnb9j5